<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: ORBIMED ADVISORS LLC -->
          <cik>0001055951</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0002036042</issuerCik>
      <issuerName>Sionna Therapeutics, Inc.</issuerName>
      <secFileNumber>001-42504</secFileNumber>
      <issuerAddress>
        <com:street1>21 HICKORY DRIVE</com:street1>
        <com:street2>SUITE 500</com:street2>
        <com:city>WALTHAM</com:city>
        <com:stateOrCountry>MA</com:stateOrCountry>
        <com:zipCode>02451</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>617-819-2020</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>OrbiMed Private Investments VIII, LP</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Shareholder</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>TD Cowen</name>
        <address>
          <com:street1>599 Lexington Avenue</com:street1>
          <com:city>New York</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10022</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>1047770</noOfUnitsSold>
      <aggregateMarketValue>46500032.60</aggregateMarketValue>
      <noOfUnitsOutstanding>44628788</noOfUnitsOutstanding>
      <approxSaleDate>11/24/2025</approxSaleDate>
      <securitiesExchangeName>Nasdaq Stock Market</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>02/10/2025</acquiredDate>
      <natureOfAcquisitionTransaction>IPO</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>1047770</amountOfSecuritiesAcquired>
      <paymentDate>02/10/2025</paymentDate>
      <natureOfPayment>Cash</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks>OrbiMed Capital GP VIII LLC is the general partner of OrbiMed Private Investments VIII, LP. OrbiMed Advisors LLC is the managing member of OrbiMed Capital GP VIII LLC.</remarks>
    <noticeSignature>
      <noticeDate>11/24/2025</noticeDate>
      <planAdoptionDates>
        <planAdoptionDate>02/10/2025</planAdoptionDate>
      </planAdoptionDates>
      <signature>/s/ Douglas Coon, Chief Compliance Officer, OrbiMed Advisors LLC, managing member of the general partner of OrbiMed Private Investments VIII, LP</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
